Anticancer Inhibitors
The word "cancer" is associated with at least 100 different pathologies, depending on the organ involved and the type of tumor developed. Cancer is a complex disease involving multiple pathogenetic mechanisms. Characterization of different types of cancers, which distinguishes them from he...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (216 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993560435804498 |
|---|---|
| ctrlnum |
(CKB)5680000000080839 (oapen)https://directory.doabooks.org/handle/20.500.12854/92104 (EXLCZ)995680000000080839 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Fantacuzzi, Marialuigia edt Anticancer Inhibitors Basel MDPI Books 2022 1 electronic resource (216 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Open access Unrestricted online access star The word "cancer" is associated with at least 100 different pathologies, depending on the organ involved and the type of tumor developed. Cancer is a complex disease involving multiple pathogenetic mechanisms. Characterization of different types of cancers, which distinguishes them from healthy cells and other cancers, allows for the identification of specific targets for each individual tumor. The principle of chemotherapy is based on interference with the mechanisms that regulate the life and proliferation of cancer cells, causing their death. In recent years, there has been continuous progress in the development of therapeutic agents against cancer, which is ongoing.The Anticancer Inhibitors Special Issue focuses on new target-based anticancer agents that inhibit a specific target involved in the suppression of various types of cancer and the control of their chemoresistance.There is a collection of research and review articles on advances in drug discovery, design, and development of new inhibitor compounds with potency against various cancer types. English Research & information: general bicssc Chemistry bicssc breast cancer tamoxifen LY294002 synergism apoptosis cell cycle tea (Camellia sinensis) flowers BTFS A2780/CP70 ovarian cancer cells S phase cell cycle arrest nicotinamide phosphoribosyltransferase NAD+ biosynthesis inhibitor azacyclohexane anticancer drug drug design enthalpy effect NSCLC Cathepsin K cell proliferation cell migration cell invasion mTOR isatin-hydrazones cytotoxicity CDK2 inhibitor ATP competitive inhibitor ADME analysis receptor tyrosine kinases protein-protein interactions protein engineering directed evolution angiogenesis binding affinity agonistic activity saponins phytochemicals tea (Camellia sinensis) flower ovarian cancer autophagy ZMYND8 tumorigenesis epigenetic regulation pro-oncogenic effects tumor suppression tacrine-coumarin derivatives DNA topoisomerases I, II lung carcinoma cells A549 chemotherapy prodrug drug targeting overexpressed enzymes ADC ADEPT GDEPT LEAPT PROTAC cyclin-dependent kinase cancer resistance small molecule inhibitors PROTACs statins pancreatic cancer DNA microarray pitavastatin cerivastatin simvastatin fluvastatin atorvastatin pravastatin HMG-CoA reductase inhibitors 3-0365-4920-X 3-0365-4919-6 Ammazzalorso, Alessandra edt Fantacuzzi, Marialuigia oth Ammazzalorso, Alessandra oth |
| language |
English |
| format |
eBook |
| author2 |
Ammazzalorso, Alessandra Fantacuzzi, Marialuigia Ammazzalorso, Alessandra |
| author_facet |
Ammazzalorso, Alessandra Fantacuzzi, Marialuigia Ammazzalorso, Alessandra |
| author2_variant |
m f mf a a aa |
| author2_role |
HerausgeberIn Sonstige Sonstige |
| title |
Anticancer Inhibitors |
| spellingShingle |
Anticancer Inhibitors |
| title_full |
Anticancer Inhibitors |
| title_fullStr |
Anticancer Inhibitors |
| title_full_unstemmed |
Anticancer Inhibitors |
| title_auth |
Anticancer Inhibitors |
| title_new |
Anticancer Inhibitors |
| title_sort |
anticancer inhibitors |
| publisher |
MDPI Books |
| publishDate |
2022 |
| physical |
1 electronic resource (216 p.) |
| isbn |
3-0365-4920-X 3-0365-4919-6 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT fantacuzzimarialuigia anticancerinhibitors AT ammazzalorsoalessandra anticancerinhibitors |
| status_str |
n |
| ids_txt_mv |
(CKB)5680000000080839 (oapen)https://directory.doabooks.org/handle/20.500.12854/92104 (EXLCZ)995680000000080839 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Anticancer Inhibitors |
| author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
| _version_ |
1789038446254227457 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04429nam-a2201225z--4500</leader><controlfield tag="001">993560435804498</controlfield><controlfield tag="005">20240124163300.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202209s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5680000000080839</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/92104</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995680000000080839</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fantacuzzi, Marialuigia</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anticancer Inhibitors</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI Books</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (216 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Open access</subfield><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The word "cancer" is associated with at least 100 different pathologies, depending on the organ involved and the type of tumor developed. Cancer is a complex disease involving multiple pathogenetic mechanisms. Characterization of different types of cancers, which distinguishes them from healthy cells and other cancers, allows for the identification of specific targets for each individual tumor. The principle of chemotherapy is based on interference with the mechanisms that regulate the life and proliferation of cancer cells, causing their death. In recent years, there has been continuous progress in the development of therapeutic agents against cancer, which is ongoing.The Anticancer Inhibitors Special Issue focuses on new target-based anticancer agents that inhibit a specific target involved in the suppression of various types of cancer and the control of their chemoresistance.There is a collection of research and review articles on advances in drug discovery, design, and development of new inhibitor compounds with potency against various cancer types.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research & information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemistry</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tamoxifen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LY294002</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">synergism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">apoptosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell cycle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tea (Camellia sinensis) flowers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BTFS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">A2780/CP70 ovarian cancer cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">S phase cell cycle arrest</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nicotinamide phosphoribosyltransferase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NAD+ biosynthesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">azacyclohexane</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anticancer drug</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug design</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">enthalpy effect</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NSCLC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cathepsin K</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell proliferation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell migration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell invasion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">isatin-hydrazones</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytotoxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CDK2 inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ATP competitive inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADME analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">receptor tyrosine kinases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protein-protein interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protein engineering</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">directed evolution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">angiogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">binding affinity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">agonistic activity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">saponins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phytochemicals</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tea (Camellia sinensis) flower</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ovarian cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autophagy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ZMYND8</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumorigenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epigenetic regulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pro-oncogenic effects</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor suppression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tacrine-coumarin derivatives</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">topoisomerases I, II</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung carcinoma cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">A549</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prodrug</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug targeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">overexpressed enzymes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADEPT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">GDEPT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LEAPT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PROTAC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cyclin-dependent kinase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">small molecule inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PROTACs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">statins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pancreatic cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA microarray</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pitavastatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cerivastatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">simvastatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fluvastatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">atorvastatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pravastatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HMG-CoA reductase inhibitors</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4920-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4919-6</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ammazzalorso, Alessandra</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fantacuzzi, Marialuigia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ammazzalorso, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-01-25 02:20:51 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-09-22 08:09:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5344130510004498&Force_direct=true</subfield><subfield code="Z">5344130510004498</subfield><subfield code="b">Available</subfield><subfield code="8">5344130510004498</subfield></datafield></record></collection> |